Our study unveils EGFR‐STAT3 as an axis of oncogenic signaling driven by overexpression of the ETS transcription factor ETV1 and provides supporting evidence for the therapeutic potential of combining EGFR and STAT3 inhibitors in targeting (prostate) carcinomas with ETV1 overexpression. The gene discussed is STAT3; the disease is carcinoma.